Page 8 - 4TH CONGRESS OF THE SERBIAN ASSOCIATION FOR CANCER RESEARCH
P. 8
㽠ʥ ÊÄãÄãÝ
PROGRAMME. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I
PREǧMEETING EDUCATIONAL SYMPOSIUM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
APPLYING TRANSLATIONAL CANCER RESEARCH IN MOLECULAR DIAGNOSTICS: SERBIAN
EXPERIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Hereditary breast/ovarian cancer: Challenges of next generation sequencing . . . . . . . . . . 1
Pharmacogenetics in clinical practice: how far have we come? . . . . . . . . . . . . . . . . . . . . . . . .2
Detection of minimal residual disease in leukemia and lymphoma: are we changing
deƤ nition and concept? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
How to estimate the indications for use of adjuvant chemotherapy in patients with
luminal HER2 negative breast cancer: the role of uPA and PAI-1 biomarkers. . . . . . . . . . . . .4
uPA and PAI-1: prognostic factors for early breast cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
SESSION: NEW TECHNOLOGIES AND APPROACHES OF MOLECULAR DIAGNOSTICS IN
HEREDITARY CANCER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
The relevance of molecular diagnostics in hereditary cancer. . . . . . . . . . . . . . . . . . . . . . . . . .6
The importance of panel testing in high grade serous ovarian cancer . . . . . . . . . . . . . . . . . .7
SESSION: TARGETED & IMMUNOTHERAPY IN CANCER: BIOMARKERǧBASED APPROACHES . .8
Focus on lung adenocarcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
Focus on melanoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
PLENARY LECTURE: Disentangling the molecular drivers of prostate cancer progression.
A career in research: Pitfalls, drawbacks and perspectives. . . . . . . . . . . . . . . . . . . . . . . . . . . 10
SESSION: CURRENT CHALLENGES AND FUTURE PERSPECTIVES OF RADIOTHERAPY . . . . . . . 11
DNA methylation as a potential predictor of tumor response to radiotherapy . . . . . . . . . 11
The role of single nucleotide polymorphisms in outcome and toxicity of radiotherapy for
prostate cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Comet assay as a tool for evaluation of DNA damage in cancer patient treated with
radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Late genitourinary toxicity after conventionally fractionated conformal radiotherapy for
localized prostate cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Pediatric radiotherapy at IORS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
